Sitemap > Breaking Research > Immunology & Inflammatory Diseases
Displaying 851 - 900 of 5698 results
- Involvement of the Rho-kinase/myosin light chain kinase pathway on human monocyte chemotaxis induced by ATL-1, an aspirin-triggered lipoxin A4 synthetic analog.
- The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production.
- The inflammatory versus constitutive trafficking of mononuclear phagocytes into the alveolar space of mice is associated with drastic changes in their gene expression profiles.
- Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis.
- Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts.
- Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein.
- Antigen-based therapies using ignored determinants of beta cell antigens can more effectively inhibit late-stage autoimmune disease in diabetes-prone mice.
- Gene targeting by ribozyme against TNF-alpha mRNA inhibits autoimmune arthritis.
- Adalimumab for treating rheumatoid arthritis.
- Inhaled beta2-agonists for treating non-specific chronic cough in children.
- Oral corticosteroids for stable chronic obstructive pulmonary disease.
- Treatment persistence with leukotriene receptor antagonists and inhaled corticosteroids.
- Eosinophils from asthmatics release IL-5 in an autocrine fashion to prevent apoptosis through upregulation of Bcl-2 expression.
- Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death.
- Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.
- G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow.
- Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice.
- Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8.
- hKSR-2 inhibits MEKK3-activated MAP kinase and NF-kappaB pathways in inflammation.
- Thioredoxin suppresses airway hyperresponsiveness and airway inflammation in asthma.
- All-trans retinoic acid biases immune response induced by DNA vaccine in a Th2 direction.
- Improving the ex vivo retroviral-mediated suicide-gene transfer process in T lymphocytes to preserve immune function.
- Effect of a novel immunosuppressant, ST1959, on the immune system and renal allograft survival in rats.
- Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study.
- Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade.
- The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria.
- Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
- Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment.
- Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
- The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
- Modulation of inflammation by kininogen deficiency in a rat model of inflammatory arthritis.
- Dipeptidyl peptidase I regulates the development of collagen-induced arthritis.
- Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus.
- Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis.
- ROS generated by pollen NADPH oxidase provide a signal that augments antigen-induced allergic airway inflammation.
- Transgenic mouse expressing human CCR5 as a model for in vivo assessments of human selective CCR5 antagonists.
- Development of dual-acting benzofurans for thromboxane A2 receptor antagonist and prostacyclin receptor agonist: synthesis, structure-activity relationship, and evaluation of benzofuran derivatives.
- Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.
- Insights into the human CD59 complement binding interface toward engineering new therapeutics.
- Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
- Microglia Kv1.3 channels contribute to their ability to kill neurons.
- A high-density screen for linkage in multiple sclerosis.
- SIRPbeta1 is expressed as a disulfide-linked homodimer in leukocytes and positively regulates neutrophil transepithelial migration.
- Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase.
- Cutting edge: critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance.
- Cutting edge: chemoattractant receptor-homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitment.
- Cutting edge: polymorphisms in the ICOS promoter region are associated with allergic sensitization and Th2 cytokine production.
- A role for IL-27 in early regulation of Th1 differentiation.
- Resistance to myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis by death receptor 6-deficient mice.
- Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 Next >